About your Search

20130416
20130424
Search Results 0 to 1 of about 2
for that kind of product. we think there's significant growth opportunities there. >> how as technology enabled new things in your business? i think the marriage of technology and health care has been so exciting. >> yeah. well, innovation is what we're all about and technology. it really starts with us being able to better target compounds and pharmaceuticals. in all areas now. we talk a lot about personalized medicine. i think we're making great strides. it's difficult science. we still have a lot of work to do. our ability to better detect who's going to respond to a particular therapy for the clinical development process has improved dramatically. that's why we're starting to see products through earlier. the other area i'm excited about is convergent technologies. how do you take a device along with a pharmaceutical product, which johnson & johnson is perfectly suited to do, and really transform the way patients are treated? that's another exciting -- >> also transformative what you're doing in oncology. talk to us about the products in the pipeline in terms of oncology. where are we in th
of technologies to the clouds. so that's the good news for intel. the bad news is they have virtually zero footprint in smart phones and tablets, at least from a processing perspective and they've been showing very little progress on that front in recent quarters and years. >> okay. and would you put money to work in intel right here? how do you want to play this story? >> right now, the most attractive thing about intel is its 4% dividend yield. i really think it's going to be a market performer, just rising and falling with economic sen m sentiment here for the foreseeable future. and i think they need to put a mobile strategy in place that shows some real promise. >> that's a great point. certainly something that we will discuss with stacy smith, the cfo, coming up in the program. anything else you want to hear from stacy smith, alex? >> we really want to hear if and how they can get to their prior guidance for low single digits growth. pcs look like they're declining, yet the company's prior guidance was to get to growth for this year, and it just does not look like that's on the tabl
Search Results 0 to 1 of about 2

Terms of Use (10 Mar 2001)